Aptevo Therapeutics APVO

Aptevo Therapeutics Inc is a clinical stage research and development biotechnology company focused on creating novel immunotherapy candidates for the treatment of cancer.
The company was incorporated in Delaware in February 2016 and became an independent publicly traded entity after a spin off from Emergent BioSolutions Inc in August 2016.
Aptevo Therapeutics Inc concentrates its efforts on oncology indications leveraging two proprietary protein technology platforms named ADAPTIR and ADAPTIR FLEX.
These platforms enable the design of monospecific bispecific and multi specific antibodies that can engage immune cells and tumor antigens simultaneously.
The lead clinical candidate mipletamig is a bispecific molecule that targets CD123 and CD3 to redirect T cells against acute myeloid leukemia cells.
Another clinical candidate ALG APV 527 targets the co stimulatory receptor 4 1BB and the tumor antigen 5T4 to activate immune cells in solid tumor indications.
In addition to these two clinical stage assets the company maintains a pipeline of six preclinical candidates that explore various immune checkpoints and tumor associated antigens.
All of these molecules are built using the ADAPTIR or ADAPTIR FLEX platforms giving the company flexibility to pursue multiple mechanisms of action.

Aptevo Therapeutics Inc does not yet generate revenue from product sales because its candidates remain in clinical or preclinical development.
The primary source of revenue comes from collaboration agreements and licensing arrangements with partners such as Alligator Bioscience.
Under the collaboration agreement with Alligator Bioscience the parties share revenue from any future commercialization of ALG APV 527 either equally or in proportion to the costs each party bears.
The agreement also includes potential milestone payments that become payable upon achievement of predefined development and regulatory milestones.
In addition Aptevo Therapeutics Inc may receive research funding and grant support from governmental or non governmental organizations that advance its pipeline programs.
The company also pursues opportunistic licensing of its platform technologies to third parties which could yield upfront fees and royalties.
Although current revenue is modest the collaboration model provides a non dilutive funding source to support ongoing research and development activities.

Aptevo Therapeutics Inc positions itself within the competitive landscape of bispecific antibody therapeutics for cancer treatment.
The broader bispecific field has seen fifteen approved agents to date of which eleven are indicated for oncology according to publicly available data from the FDA.
Companies such as Affimed ImmunoGen Innate Pharma Macrogenics Gilead Sanofi and others are active in developing similar bispecific molecules for hematologic and solid tumor indications.
Aptevo Therapeutics Inc differentiates itself through its proprietary ADAPTIR and ADAPTIR FLEX platforms that allow rapid generation of diverse molecular formats without sacrificing manufacturability or half life.
The platform's ability to incorporate a unique CRIS 7 derived CD3 binding domain contributes to a differentiated safety profile for mipletamig marked by low rates of cytokine release syndrome in clinical trials.
The orphan drug designation granted by the FDA for mipletamig in acute myeloid leukemia provides potential market exclusivity and regulatory advantages that few competitors possess for this indication.
Additionally the company's partnership with Alligator Bioscience brings external expertise and shared intellectual property which enhances the development of ALG APV 527.
Collectively these factors give Aptevo Therapeutics Inc a competitive niche in the bispecific immuno oncology space.

Aptevo Therapeutics Inc serves patients diagnosed with cancer who are eligible to participate in its clinical trials across various medical centers and hospitals.
The company interacts with healthcare providers including oncologists nurses and pharmacists who administer investigational drugs and monitor patient safety during study visits.
Clinical trial sites are typically located in academic medical centers community hospitals and specialty oncology clinics that have the infrastructure to support early phase research.
Beyond direct patient care Aptevo Therapeutics Inc engages with collaboration partners such as Alligator Bioscience which contributes scientific expertise and shares in the development risks and rewards of joint programs.
The company also communicates with regulatory agencies and investor groups to keep stakeholders informed of progress and milestones.
Specific customer names are not disclosed in the filing but the overall customer base consists of patients medical institutions and collaborative biotechnology firms.